Benzinga | Jan 19, 2022 08:37AM EST

NanoVibronix Reports Filed 3 US Patent Applications To Leverage Surface Acoustic Wave Technology

Creates Pathway to Launch of New Innovative Products

ELMSFORD, N.Y.--(BUSINESS WIRE)-- NanoVibronix Inc., (NASDAQ:NAOV), a medical device company that produces the UroShield(r) and PainShield(r) Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has filed three U.S. patent applications with the U.S. Patent & Trademark Office related to its SAW technology and indwelling medical devices to protect targeted new product launches and improvements to existing medical devices.

Brian Murphy, Chief Executive Officer of NanoVibronix Inc., commented, "Our patented SAW ultrasound technology has proven effective in treating pain, as well as inhibiting infections associated with urological conditions. Beyond just urology and pain management, our expanding patent portfolio is driven by our commitment to continue exploring different applications and developing new products that leverage our unique technology.

"For example," noted Murphy, "one of our new applications relates to cosmetic applications of our technology to reduce signs of aging and improve skin texture. In line with the growing use of ultrasound in cosmetic dermatology, our SAW-generating devices and facial patches address a host of cosmetic and topical concerns. Importantly, this represents a new and sizeable market opportunity for us."

"In addition, we believe that we have made material improvements to the assembly and operational configuration of indwelling medical devices incorporating our SAW-generating technology," added Murphy. "The new patent applications provide for new stand-alone devices, such as a novel catheter, intravenous (IV) needle assembly and percutaneous endoscopic gastrostomy (PEG) tube. More generally, described in the new applications is an ultrasound system that effectively transforms any such indwelling medical device into a therapeutic device. The generation of SAW along the surface of our indwelling medical devices produces nano-vibrations sufficient to inhibit the colonization of bacteria and, as a result, the formation of bacterial biofilms that are commonly known to adhere to surfaces of conventional indwelling devices. Therefore, we believe that a significant improvement of our indwelling devices is the accompanying antimicrobial prophylactic effect for preventing infections associated with conventional indwelling medical devices. Given that infections stemming from indwelling devices account for up to twenty percent of annual healthcare-associated infections in hospitalized patients, coupled with the resulting prolonged hospitalization stays and increased costs per admission, our technology should provide readily recognized and broadly applicable advantages."